Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

3Total
P 1 (1)
P 2 (2)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT00454363Phase 2Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

NCT01010126Phase 2Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

NCT01204476Phase 1Completed

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Showing all 3 trials

Research Network

Activity Timeline